



(51) International Patent Classification:

A61K 38/26 (2006.01) A61P 3/00 (2006.01)
C07K 14/605 (2006.01)

(21) International Application Number:

PCT/US2018/065663

(22) International Filing Date:

14 December 2018 (14.12.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/608,613 21 December 2017 (21.12.2017) US

(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: ALSINA-FERNANDEZ, Jorge; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). COSKUN, Tamer; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). GUO, Lili; c/o Eli Lilly and Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).
QU, Hongchang; c/o Eli Lilly and Company, P.O. Box
6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: CHOLEWA, Brian C. et al.; Eli Lilly and Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: INCRETIN ANALOGS AND USES THEREOF

(57) Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.

